EHA 2021 | Phase II trial-in-progress of itacitinib in patients with myelofibrosis

Name: Phase II trial-in-progress of itacitinib in patients with myelofibrosis
Uploaded: 2021-06-08T00:00:00Z
Duration: 1 min 49 s

Andrew Kuykendall • 8 Jun 2021

EHA 2021

Myelofibrosis Fedratinib Itacitinib Ruxolitinib

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL provides background on itacitinib, a potent JAK inhibitor, and shares an update on the Phase II study of itacitinib immediate release in patients with primary or secondary myelofibrosis, who have previously received ruxolitinib and/or fedratinib monotherapy. The Phase II study is designed to determine a tolerable and safe dose of itacitinib immediate release and whether that dose results in clinically significant reductions in symptoms and spleen volume in myelofibrosis patients at week 24. Dr Kuykendall discusses the rationale for the trial-in-progress. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.